CORO1B

Across TCGA pan-cancer cohorts, CORO1B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CORO1B data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CORO1B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CORO1B expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where CORO1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.940	0.439	.008	20	view →
LSCC	DFS	Tertile	III,IV	0.408	0.894	.008	10	view →
CCRCC	OS	Median	III,IV	0.817	0.588	.012	8	view →
LUAD	OS	Tertile	II,III,IV	0.407	0.780	.014	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CORO1B–PDAC (DFS)

Open the PDAC breakdown →